Molecular docking analysis of α-Synuclein aggregation with Anle138b

Area of Science:

• Neuroscience
• Computational Biology
• Pharmacology

Background:

• Alpha-synuclein aggregation into toxic oligomers is central to Parkinson's disease (PD) pathogenesis.
• Anle138b is a novel inhibitor demonstrating preclinical promise for targeting alpha-synuclein oligomerization.

Purpose of the Study:

• To elucidate the oligomer-specific mechanism of action for Anle138b.
• To provide molecular insights into Anle138b's therapeutic potential for Parkinson's disease and related synucleinopathies.

Main Methods:

• Molecular docking studies using AutoDock Tools to evaluate Anle138b's binding affinity to alpha-synuclein oligomers.
• Binding pocket analysis of Anle138b within alpha-synuclein oligomers.
• Protein-protein docking using Hex8.0 to validate Anle138b's aggregation inhibitory potential.

Main Results:

• Anle138b exhibited increasing binding affinity for higher-order alpha-synuclein oligomers (dimer to decamer).
• Anle138b was found to occupy oligomeric cavities and interact with key residues (Thr54, Gly73, Val74, Thr75).
• Protein-protein docking confirmed Anle138b's interference with alpha-synuclein decamer formation.

Conclusions:

• Anle138b demonstrates an oligomer-directed inhibitory mechanism, selectively targeting toxic aggregates without affecting monomeric forms.
• The study provides crucial molecular insights supporting the advancement of Anle138b as a therapeutic agent for synucleinopathies.